Home › UPDATE 2-Celgene to stop blood cancer trial due to high death rates
 

Keywords :   


UPDATE 2-Celgene to stop blood cancer trial due to high death rates

2013-07-18 23:40:32| Biotech - Topix.net

Celgene Corp said it will stop a late-stage trial of its blood cancer drug, Revlimid, after it observed a higher number of deaths in elderly leukemia patients taking the drug compared with those on another treatment.

Tags: high due rates update

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
30.09Eastern North Pacific Tropical Weather Outlook
30.09Tropical Depression Joyce Forecast Advisory Number 11
30.09California governor blocks landmark AI safety bill
30.09Tropical Storm Isaac Graphics
30.09Tropical Storm Isaac Forecast Discussion Number 17
30.09Tropical Storm Isaac Wind Speed Probabilities Number 17
30.09Tropical Storm Isaac Forecast Advisory Number 17
30.09Tropical Storm Isaac Public Advisory Number 17
More »